Ocata Therapeutics Company
%20.jpg)
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Estimated Revenue:
$10M to $50M
Funding Status:
M&A
Industry:
Biotechnology, Health Care, Therapeutics
Investors Number:
13
Technology:
Regenerative Medicine
Founded Date:
1-1
Investor Type:
For Profit
Headquarters:
Marlborough, Massachusetts, United States
Total Funding:
$82.5M
Last Funding Type:
Venture - Series Unknown
Employee Number:
11-50